Company profile
Theravance Biopharma Inc
NASDAQ: TBPH · Healthcare · Biotechnology
#343 of 1,422 Healthcare companies by revenuetop-decile growth
EA Score
75B+FH 88DQ 61GM 69SS 65
v0.1 · 65/100 weight · provisional
↑ net margin, return on assets · ↓ growth stability, filing timeliness
Methodology →Revenue TTM
$109.8M
Rev growth YoY (TTM)
+68.2%
Net income (FY)
$105.9M
Employees
90
as of 2026-08-10
Market cap
$877.5M
as of 2026-08-10
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$107.5M$107.5M2025
Net income$105.9M$105.9M2025
Operating income-$3.6M-$3.6M2025
Total assets$485.6M$485.6M2025
Equity$296.7M$296.7M2025
Revenue trend
FY2024 – FY2025 · USD
FY24
FY24
FY24
FY24
FY25
FY25
FY25
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Collaborative Arrangement Revenue70%
Milestone23%
License7%
By geography
UNITED STATES70%
Europe30%
The read
What is Theravance Biopharma Inc’s revenue?
Theravance Biopharma Inc booked $107.5M in FY2025 revenue, growing 438% year over year — faster than 94% of Healthcare companies we track, at a 98.5% net margin.
Peers · Healthcare
OptimizeRx Corp.72BCentury Therapeutics, Inc.48DAuxly Cannabis Group Inc.76B+Zevra Therapeutics, Inc.70BZymeworks Inc.55COwlet, Inc.49DNeighbors
San Mateo →Key facts
CEORick E. Winningham
SectorHealthcare
IndustryBiotechnology
HeadquartersSouth San Francisco, CA
ExchangeNASDAQ: TBPH
Employees90
IPO date2014-05-16
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.